The rise of direct-to-patient services
The COVID-19 pandemic has significantly disrupted clinical trials, yet the industry is adapting and finding opportunities and new ways to serve patients. Logistical challenges, including the inability of patients to attend clinics has placed added emphasis on Direct-to-Patient (DtP) services.
So, in the current climate why should DtP clinical trial material shipments be integrated into your study?
A patient-centric approach that complies with Covid restrictions
The demand for more patient-centric trials has been mounting so this isn’t a new discussion. However, due to Covid restrictions across the globe and the risk of vulnerable patients attending clinics, solutions such as DtP shipments of Investigational Medicinal Products (IMP) and remote treatment of patients have become necessary. Remote clinical trials are more appealing to participate in, as risks are minimised, enhancing patient experience and adherence while reducing dropouts from the trials.
Long-term patient benefits
DtP shipments not only benefit patients during the current pandemic, but will also help in the long-term as patients can continue to participate in clinical trials from the comfort of their own home. These positive measures reduce unnecessary trips to clinics and hospitals, making trials more convenient for patients while freeing capacity in heath-centres.
Easier patient recruitment
The convenience of remote trials makes it easier to recruit and retain patients; data indicates the use of DtP services helps to maintain patient retention rates at more than 95 percent, highlighting the effectiveness of this approach to support clinical trial success.
Complete trials faster and more efficiently
DtP services have been found to accelerate the completion of trials and overall drug development. Specifically and relevant to the current climate, this shipping approach provides the ability to continually supply clinical trial materials without suspending or disrupting the study – delivering a personalised approach to meet clinicians’ and patients’ needs within specific timeframes.
The FDA has recently updated guidance on switching to virtual models, further demonstrating regulatory backing.
Talk to us today about our DtP services: https://www.wasdell.co.uk/contact/